Cwm LLC Purchases 2,042 Shares of Blueprint Medicines Corporation (NASDAQ:BPMC)

CWM LLC increased its stake in Blueprint Medicines Corporation (NASDAQ:BPMC - Free Report) by 62.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,321 shares of the biotechnology company's stock after purchasing an additional 2,042 shares during the quarter. CWM LLC's holdings in Blueprint Medicines were worth $471,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in Blueprint Medicines by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 6,774,884 shares of the biotechnology company's stock worth $590,905,000 after buying an additional 91,450 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Blueprint Medicines by 5.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,679,089 shares of the biotechnology company's stock worth $495,331,000 after buying an additional 291,822 shares during the last quarter. Wellington Management Group LLP increased its holdings in Blueprint Medicines by 8.0% in the fourth quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock worth $373,421,000 after buying an additional 316,754 shares during the last quarter. Geode Capital Management LLC increased its holdings in Blueprint Medicines by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 1,490,101 shares of the biotechnology company's stock worth $129,996,000 after buying an additional 9,914 shares during the last quarter. Finally, Avoro Capital Advisors LLC acquired a new position in Blueprint Medicines in the fourth quarter worth approximately $103,356,000.

Analyst Ratings Changes

Several research analysts recently commented on the company. Citigroup raised Blueprint Medicines from a "strong sell" rating to a "hold" rating and raised their target price for the stock from $83.00 to $129.00 in a research report on Wednesday, June 4th. Wall Street Zen raised Blueprint Medicines to a "hold" rating in a report on Friday, July 18th. JMP Securities reaffirmed a "market perform" rating on shares of Blueprint Medicines in a report on Tuesday, June 3rd. Scotiabank cut Blueprint Medicines from a "strong-buy" rating to a "sector perform" rating and set a $135.00 price target for the company. in a report on Monday, June 2nd. Finally, Guggenheim set a $132.00 price target on Blueprint Medicines in a report on Tuesday, June 3rd. Eighteen research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $128.25.

Blueprint Medicines Price Performance

Shares of NASDAQ:BPMC remained flat at $129.46 during trading on Friday. Blueprint Medicines Corporation has a 52-week low of $73.04 and a 52-week high of $129.65. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 1.01. The stock has a market capitalization of $8.36 billion, a price-to-earnings ratio of -52.41 and a beta of 0.89. The company's 50-day moving average is $122.99 and its two-hundred day moving average is $104.52.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.32). Blueprint Medicines had a negative net margin of 27.70% and a negative return on equity of 64.60%. The business had revenue of $149.41 million for the quarter, compared to the consensus estimate of $158.31 million. During the same quarter last year, the firm earned $1.40 EPS. The company's revenue for the quarter was up 55.5% on a year-over-year basis. Equities analysts expect that Blueprint Medicines Corporation will post -1.28 EPS for the current year.

Insiders Place Their Bets

In other Blueprint Medicines news, insider Ariel Hurley sold 2,752 shares of the business's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $103.13, for a total value of $283,813.76. Following the sale, the insider owned 16,944 shares in the company, valued at approximately $1,747,434.72. The trade was a 13.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $101.14, for a total value of $505,700.00. Following the completion of the sale, the director owned 146,630 shares in the company, valued at $14,830,158.20. The trade was a 3.30% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 13,351 shares of company stock worth $1,384,244. Company insiders own 4.21% of the company's stock.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.